Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 16, 2010
Quantifying and predicting the promiscuity and isoform specificity of small-molecule cytochrome P450 inhibitorsAbhinav Nath, Michael A Zientek, Benjamin J Burke, et al.Bioorganic & Medicinal Chemistry|May 13, 2015
Effect of water solvation on the lipophilicity of isomeric pyrimidine-carboxamidesMaria Angelica Linton, Benjamin J Burke, Ted W Johnson, et al.Proceedings of the National Academy of Sciences of the United States of America|July 10, 2021
1,2-Difunctionalized bicyclo[1.1.1]pentanes: Long-sought-after mimetics for ortho/meta-substituted arenesJin-Xin Zhao, Yu-Xuan Chang, Chi He, et al.Journal of Chemical Theory and Computation|December 29, 2023
Development and Comprehensive Benchmark of a High-Quality AMBER-Consistent Small Molecule Force Field with Broad Chemical Space Coverage for Molecular Modeling and Free Energy CalculationBai Xue, Qingyi Yang, Qiaochu Zhang, et al.The New England Journal of Medicine|December 25, 2015
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198FAlice T Shaw, Luc Friboulet, Ignaty Leshchiner, et al.Journal of Medicinal Chemistry|September 23, 2011
Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonistsChuangxing Guo, Angelica Linton, Susan Kephart, et al.Journal of Medicinal Chemistry|November 2, 2011
Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1)Sean T Murphy, Gordon Alton, Simon Bailey, et al.Cancer Discovery|April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung CancerSatoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.ACS Medicinal Chemistry Letters|June 20, 2020
Characterization of Specific N-α-Acetyltransferase 50 (Naa50) Inhibitors Identified Using a DNA Encoded LibraryPei-Pei Kung, Patrick Bingham, Benjamin J Burke, et al.Journal of Medicinal Chemistry|May 14, 2014
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutationsTed W Johnson, Paul F Richardson, Simon Bailey, et al.Pageof 2